APA (7th ed.) Citation

VE, K., CAC, P., A, W., B, C., Y, S., JE, H., . . . CC, S. (2026). Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy. Blood. https://doi.org/10.1182/blood.2025032466

Chicago Style (17th ed.) Citation

VE, Kennedy, et al. "Dynamic Genetic and Nongenetic RAS Pathway Activation Drives Resistance to FLT3 and BCL2 Inhibitor Therapy." Blood 2026. https://doi.org/10.1182/blood.2025032466.

MLA (9th ed.) Citation

VE, Kennedy, et al. "Dynamic Genetic and Nongenetic RAS Pathway Activation Drives Resistance to FLT3 and BCL2 Inhibitor Therapy." Blood, 2026, https://doi.org/10.1182/blood.2025032466.